CLINICAL TRIALS
CAPRI Phase III
Investigator physician : Pr Pierre-Yves MARIE
Assessment of the 18F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis
Amyloidosis
DORA Not applicable
Investigator physician : Pr Antoine VERGER
Contribution of Cerebral 18F-DOPA PET-CT Scan in High-grade Recurrent Gliomas : a Monocentric Pilot Impact Study on the Practices of Defining Target Volumes Before RAdiotherapy
Gliioma
DOTENDO Phase II
Investigator physician : Dr Caroline BOURSIER
Early feasibility study of somatostatin receptor PET imaging for the diagnosis of infective endocarditis
Infective endocarditis
EVADOVE 177Lu Not applicable
Investigator physician : Dr Elodie CHEVALIER
Evaluation d’une méthode de dosimétrie en routine clinique en caméra VERITON-CT™ chez des patients traités par Lutathera [177Lu- [DOTA0, Tyr3] -octréotate
Patients receiving Luthatera ® therapy
GATEDOTA Not applicable
Investigator physician : Dr Mathieu PERRIN
GATED cardiac analysis in patients with 68GA-DOTATOC PET for oncological indications
Diagnostic or pre-therapeutic workup or follow-up of a neuroendocrine tumor
TEP-COV Not applicable
Investigator physician : Pr Antoine VERGER
18F-FDG PET/CT characterization of brain lesions in young subjects with sequelae of psycho-cognitive disorders in the aftermath of severe Covid-19
Sequelae of psycho-cognitive disorders following severe Covid-19
VERICATH Clinical investigation according to RE 2017/745
Investigator physician : Dr Elodie CHEVALIER
Évaluation d’une procédure d’enregistrement corps entier 3D en caméra CZT « VERITON-CT™ » : Comparaison à la procédure classique d’enregistrement 2D corps entier associée à des tomoscintigraphies complémentaires chez des patients ayant reçu un traitement par Iode 131 pour un Cancer Thyroïdien
Thyroid cancer patients for whom multidisciplinary consultation meeting has validated iratherapy treatment
PERQUAL Not applicable
Investigator physician : Dr Achraf BAHLOUL
Diagnostic performance of SPECT/CT bone scan quantification prior to lumbar arthodesis surgery
People with back pain for at least 3 months (presumed to be due to degenerative discarthrosis or spondylolisthesis)
KING Phase IIIb
Investigator physician : Pr Antoine VERGER
Evaluation of diagnostic performances of 18F-FDOPA PET KInetics as biomarkers for the improvement of care of MRI Non-contrast enhanced Gliomas
Suspicion of Glioma with MRI non contrast enhanced
HYDEM Not applicable
Investigator physician : Martine Louis
Randomized controlled trial evaluating the efficacy of HYpnosis using a DEported method adapted to Nuclear Medicine versus hypnosis using a conventional method
Ericksonian hypnosis session given to patients during a scintigraphic or PET examination in a remote setting
PSMA Addition Phase III
Médecin investigateur : Pr Pierre OLIVIER
An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
ECLIPSE Phase III
Médecin investigateur : Pr Pierre OLIVIER
A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
DATTEP Phase III
Médecin investigateur : Dr Lucie HOPES
Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor
Parkinson et Tremblement Essentiel
MIBI Thyr Not applicable
Médecin investigateur : Pr Laurent BRUNEAU
Interest of the combination of ultrasound with Ti-RADS score / dual tracer MIBI-Tc99m/Iodine-123 scintigraphy in the detection of malignancy of thyroid nodules (≥ 15 mm) classified Bethesda III or IV in cytopuncture
Thyroid nodules (≥ 15 mm) classified as Bethesda III or IV on cytopuncture
PROACTIF - BTG 007996-01 Phase IV / Registre
Médecin investigateur : Dr Elodie CHEVALIER
A prospective, post-authorization, multicenter, open-label, non-interventional registry study to evaluate the efficacy of TheraSphere® in clinical practice in France
Unresectable hepatocellular carcinoma (HCC)
ReLUTH Phase II
Médecin investigateur : Dr Elodie CHEVALIER
A prospective randomized phase ii study to assess the schemas of retreatment with lutathera® ([177Lu]lu-dota-tate) in patients with new progression of intestinal well-differentiated neuroendocrine tumor
intestinal well-differentiated neuroendocrine tumor
DEBIO 1228-101 PART A Phase I
Médecin investigateur : Pr Pierre OLIVIER
A multicenter, open-label, non-randomized Phase 1/2 study to assess safety,tolerability, and imaging characteristics of [68Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [177Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors
Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of:
- ccRCC: patients must have received at least one line containing TKI treatment and at least one line containing Immune Checkpoint Inhibitor treatment in metastatic setting, meaning at least two lines of treatment in metastatic setting; or
- PDAC: patients must have received at least one line of platinum- and/or gemcitabine-based regimen; or
- CRC: patients must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-VEGF or anti-EGFR
DEBIO 1228-101 PART A Phase I
Médecin investigateur : Pr Pierre OLIVIER
A multicenter, open-label, non-randomized Phase 1/2 study to assess safety,tolerability, and imaging characteristics of [68Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [177Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors
Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of:
- ccRCC: patients must have received at least one line containing TKI treatment and at least one line containing Immune Checkpoint Inhibitor treatment in metastatic setting, meaning at least two lines of treatment in metastatic setting; or
- PDAC: patients must have received at least one line of platinum- and/or gemcitabine-based regimen; or
- CRC: patients must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-VEGF or anti-EGFR
SATISFACTION Phase I/II
Médecin investigateur : Pr Pierre OLIVIER
A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with heavily pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC) with or without prior 177Lu-labelled PSMAtargeted radioligand therapy
pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC)